Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
Final decision from the European Commission is anticipated within the coming months
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
First and only PARP inhibitor to improve overall survival in early breast cancer
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Subscribe To Our Newsletter & Stay Updated
